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Objectives. This study sought to determine the prognostic
significance of serial dobutamine stress echocardiography (DSE)
in new heart transplant recipients and to examine the relation
between persistent wall motion abnormalities and the eventual
development of coronary artery disease (CAD) as assessed by
angiography.
Background. Allograft CAD is a major cause of graft failure.
However, clinical diagnosis of the early disease remains difficult.
The reasons for this include the diffuse nature of the disease and
its predilection for the microvasculature, which are not easily
detected by coronary angiography. Identifying patients at risk for
the development of angiographic CAD early after transplantation
may allow such patients to be targeted for aggressive treatment
options to prevent subsequent cardiac events and early graft
failure.
Methods. Twenty-two new heart transplant recipients were
selected to undergo serial DSE at the time of their regularly
scheduled endomyocardial biopsy. In addition, patients under-
went scheduled annual coronary angiography. DSE was per-
formed in 5-min stages with infusion of intravenous dobutamine
at 5, 10, 20, 30 and 40 mg/kg body weight per min.
Results. Twenty-two patients had 91 DSE studies and 45
coronary angiograms. The patients were categorized into three
groups based on the echocardiographic results. Group 1 (n 5 7)
had normal serial stress echocardiographic studies. Group 2 (n 5
4) had transient inducible wall motion abnormalities. Group 3
(n 5 11) developed persistent wall motion abnormalities. During
a mean follow-up time of 32 6 11 months (range 5 to 50), 8 (73%)
of 11 patients in Group 3 developed events. The events included
angiographic CAD (n 5 7), myocardial infarction (MI) (n 5 1)
and cardiac death (n 5 3). The patient who developed an MI had
a normal coronary angiogram. No cardiac event or angiographic
disease occurred in either Group 1 or 2 patients.
Conclusions. These results suggest that dobutamine-induced
wall motion abnormalities, which are persistent in new heart
transplant recipients, are predictive of the development of angio-
graphic CAD, MI or death.
(J Am Coll Cardiol 1998;31:1607–14)
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The etiology of graft failure after heart transplantation is
multifactorial. Acute cellular rejection (1–3), vascular rejection
(4,5), coronary artery disease (CAD) (6–8) and perioperative
ischemic myocardial necrosis (9) have all been reported to
contribute to cardiac allograft dysfunction. Among these,
allograft CAD is the most prevalent condition that limits
long-term graft survival (8). Allograft CAD may be an
immune-mediated process with accelerated progression. The
disease is typically silent and the diagnosis is often made at
autopsy, especially in the early months after heart transplan-
tation. The onset of allograft CAD may be diffuse, with a
predilection for the microvasculature. By the time focal
lesions are detected on the angiogram, the disease process is
advanced and the treatment option is limited to retransplan-
tation. Early detection of allograft CAD is therefore an
important step in developing effective therapeutic modali-
ties. The ability to identify patients who are at risk for
developing angiographic disease early after heart transplan-
tation may be beneficial in much the same way that endo-
myocardial biopsy helps in selecting patients who need
augmented immunosuppression.
Dobutamine stress echocardiography (DSE) is rapidly
emerging as the noninvasive test of choice in the screening for
allograft CAD (10,11) and in predicting outcome in heart
transplant recipients (12). However, it is unclear whether the
wall motion abnormalities induced during DSE have the same
implications early after transplantation. To the best of our
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knowledge, DSE has not been used in patients with a new
transplant (,2 years) in a serial fashion to assess the early
development of CAD.
Accordingly, the objectives of this study were 1) to evaluate
the ability of serial DSE to predict the eventual development
of angiographic CAD; 2) to relate the significance of persis-
tent, inducible wall motion abnormalities with outcome in
heart transplant recipients up to 2 years after transplantation;
and 3) to assess the safety of DSE soon after heart transplan-
tation.
Methods
Study group. The study included consecutive patients un-
dergoing heart transplantation at our institution. There were
32 new heart transplant operations performed from January
1992 through May 1996. Four patients died early. Of the
remaining 28 patients, four had follow-up in their respective
home towns; therefore, DSE studies were not done. One
patient developed mediastinitis and had an operation with a
mediastinal flap, making echocardiographic imaging difficult.
Another patient did not undergo serial echocardiographic
studies owing to prolonged post-transplant clinical instability.
Thus, 22 patients comprised the final study group and were
enrolled in this longitudinal study.
All patients were on a standard immunosuppression regi-
men with cyclosporin (6 mg/kg body weight per day), azathio-
prine (2 mg/kg per day) or prednisone (0.4 mg/kg per day), or
a combination of these. Two patients received OKT3 and one
other had antithymocyte globulin for prophylaxis. Acute rejec-
tion was treated with augmented immunosuppression with
steroids. No patient had any medication changes made for the
purpose of the study. Lipid profile was checked on all patients
at 1, 12 and 24 months.
According to the study design, patients underwent serial
DSE along with their routine post-transplant diagnostic eval-
uation. DSE was performed at the time of their endomyocar-
dial biopsy or diagnostic cardiac catheterization. The tests
were done within 24 h of each other. The study was approved
by the Committee on the Conduct of Human Research of the
Virginia Commonwealth University and the Research Com-
mittee of the McGuire Veterans Affairs Medical Center.
The timing of the first DSE study was decided by the
transplant team. Whenever it was decided that the patient was
stable enough to participate in the study, DSE was performed
at the time of endomyocardial biopsy. The mean time of the
first DSE study was 2 months (range 16 days to 4 months) after
heart transplantation. Coronary angiography was done within 1
year of transplantation in all patients.
Cardiac catheterization. Diagnostic cardiac catheteriza-
tion was performed in all patients as part of the routine
post-transplant evaluation. No patient underwent cardiac cath-
eterization based on the results of the stress echocardiogram.
Each patient had at least one diagnostic cardiac catheteriza-
tion performed. Selective coronary angiography was per-
formed in a standard fashion after administration of intrave-
nous nitroglycerin. Coronary stenoses were graded and
classified according to a previously published scheme by Gao et
al. (13). Focal epicardial lesions were interpreted as significant
if the lumen stenosis was .50% in at least two orthogonal
views. Small-vessel and diffuse disease without discrete lesions
were classified as such. All interpretations were done by two
experienced independent reviewers who had no knowledge of
the results of the other diagnostic tests.
Endomyocardial biopsy. Endomyocardial biopsy was per-
formed by introducing the biopsy forceps into the right ventri-
cle through a long sheath. Approximately three to four pieces
of myocardial tissue were sampled during each procedure. The
schedule for surveillance endomyocardial biopsies at our insti-
tution is as follows: weekly for the first month, biweekly for the
next month, monthly for 6 months and every other month to 18
months. After this period biopsies are taken every 3 months up
to 2 years. The biopsy specimens were analyzed by experienced
pathologists who had no knowledge of the patients’ clinical
data. Acute cellular rejection was graded according to the
International Society of Heart and Lung Transplantation
(ISHLT) criteria (14). For the purpose of this study, only grade
$2 was considered as significant allograft rejection.
Dobutamine infusion protocol. All patients were asymp-
tomatic and studied in the postabsorptive state after a 12-h
fast. In all cases DSE was performed within 24 h of either the
endomyocardial biopsy or the diagnostic cardiac catheteriza-
tion. Dobutamine infusion was begun after baseline data,
including a 12-lead electrocardiogram (ECG), blood pressure,
heart rate and echocardiographic images, were obtained. We
used the 5-min stages of 5-, 10-, 20-, 30- and 40-mg/kg per min
dobutamine infusion. Our protocol called for early termination
in case of ECG changes $2 mm ST segment depression,
symptomatic hypotension or intolerable symptoms (10).
Two-dimensional echocardiography. Two-dimensional
echocardiography was performed with a 2.5- or 3.5-MHz
transducer and commercially available scanner (Hewlett-
Packard, Sonos 1500 model 77035A). Echocardiographic im-
ages were acquired at baseline and during the last 2 min of
each infusion stage. Images were obtained in the left lateral
decubitus position and recorded on videotape. Four standard
views were obtained: parasternal long- and short-axis views and
apical four- and two-chamber views. Images were digitized and
stored on a hard drive controlled by a computer workstation
Abbreviations and Acronyms
CAD 5 coronary artery disease
DSE 5 dobutamine stress echocardiography
ECG 5 electrocardiogram, electrocardiographic
ISHLT 5 International Society of Heart and Lung
Transplantation
LAD 5 left anterior descending coronary artery
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
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(Nova Microsonics Image Vue). Digitized images were trans-
ferred to optical drive for off-line analysis.
Echocardiographic image analysis. Representative images
of each view were stored in real-time into cine loops at
baseline, 5 mg/kg per min, peak dobutamine infusion and
recovery. For this study, wall motion was read qualitatively as
normal, hypokinesia, akinesia or dyskinesia. Different myocar-
dial segments were assigned to their respective coronary
distribution. For instance, segments in the anterior, apex,
anteroseptal and mid-septal positions were assigned to the left
anterior descending coronary artery (LAD). Segments in the
posterior and lateral positions were assigned to the left cir-
cumflex coronary artery and those in the inferior position to
the right coronary artery.
Wall motion was analyzed by two experienced echocardio-
graphers who had no knowledge of the clinical data, including
coronary angiograms and biopsy results. Regional wall motion
was determined by simultaneous comparison of the cine loops.
A normal response to dobutamine was defined as augmenta-
tion of baseline systolic wall motion. A positive response was
defined as a lack of augmentation, worsening of baseline
segmental abnormality or development of a new wall motion
abnormality.
Necropsy analysis. Heart specimens from patients who
died were reviewed. Multiple sections from both ventricles as
well as from the coronary arteries were examined. The cause of
death was ascertained as cardiac or noncardiac depending on
the pathologic observations.
Statistical analysis. All data in the text and tables are
expressed as the mean value 6 SD. Differences between mean
values were analyzed by the Student t test. The relation
between abnormal tests and outcome was evaluated by using
the Fisher exact test. Event-free survival data were examined
using the Kaplan-Meier method and the Cox proportional
hazards model. Differences in survival among the groups were
determined by the Wilcoxon sign-rank test. The cutoff for
significance for all analyses was set at p # 0.05.
Results
General characteristics. This longitudinal study involved
22 asymptomatic new heart transplant recipients. All of the
study patients were men (average age 49.7 6 9.6 years). The
donor age was 28.1 6 11.3 years (range 14 to 55). The mean
donor heart ischemic time was 152 6 31 min (range 82 to 238).
Pretransplant diagnoses included ischemic cardiomyopathy
(n 5 10), dilated cardiomyopathy (n 5 11) and valvular heart
disease (n 5 1). At the time of the first study, the mean
cholesterol level was 197 6 46 mg/dl and the left ventricular
ejection fraction (LVEF) was 55 6 4%. Table 1 gives the
baseline demographic data of the study group. All 22 patients
were receiving immunosuppressive therapy with two or three
agents. Two patients had received OKT3 monoclonal antibody
and another patient antithymocyte globulin within the first 3
months of heart transplantation. The overall results of DSE,
the cardiac events and their time of onset are summarized in
Table 2. Table 3 describes the comparative demographic data
in patients with and without cardiac events.
Dobutamine stress echocardiograms. There were a total of
91 serial DSE studies performed in the 22 study patients
(Table 2). In seven patients (32%), all serial DSE images were
interpreted as normal (Group 1). In these seven, there were no
instances of inducible wall motion abnormalities on any of
their DSE studies. Four patients (18%) had dobutamine-
induced wall motion abnormalities that were nonpersistent
(Group 2). These patients developed inducible abnormalities
at one time or another, which resolved on subsequent testing.
In other words, although there had been inducible abnormal-
ities on some tests during the study, these abnormalities
Table 1. Baseline Demographic Data of Study Patients
Recipient age (yr) 49.7 6 9.6
Donor age (yr) 28.1 6 11.3
Etiology of heart failure
Ischemic cardiomyopathy 9
Dilated cardiomyopathy 12
Valvular heart disease 1
Ischemic time (min) 152 6 31
Serum cholesterol (mg/dl) 197 6 46
Baseline LVEF (%) 55 6 4
Data presented are mean value 6 SD or number of patients. LVEF 5 left
ventricular ejection fraction.
Table 2. Dobutamine Stress Echocardiographic Results, Cardiac
Events, Number of Rejection Episodes and Follow-Up Time in 22
Male Study Patients
Pt No./
Age (yr)
Serial
DSE
No. of
Rejection
Episodes Cardiac Event
Follow-Up
Time
(months)
1/54 Persistent 2 None 17
2/44 Normal 0 None 18
3/54 Persistent 0 Small-vessel CAD 46
4/62 Persistent 1 Small-vessel CAD/death 14
5/57 Persistent 0 LAD bridging 16
6/44 Persistent 0 60% stenosis of LAD/death 28
7/36 Persistent 1 Diffuse CAD 48
8/56 Persistent 0 100% stenosis of LAD 8
9/36 Persistent 0 MI (normal coronary arteries) 4
10/54 Persistent 1 60% stenosis of LAD/death 11
11/47 Persistent 1 None 28
12/57 Persistent 0 None 50
13/59 Transient 2 None 31
14/48 Transient 0 None 44
15/23 Transient 0 None 49
16/54 Normal 0 None 22
17/48 Normal 2 None 42
18/46 Normal 0 None 25
19/48 Normal 0 None 48
20/55 Normal 0 None 33
21/47 Normal 0 None 42
22/38 Transient 3 None 5
CAD 5 coronary artery disease; DSE 5 dobutamine stress echocardiogra-
phy; LAD 5 left anterior descending coronary artery; MI 5 myocardial
infarction; Pt 5 patient.
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normalized at a later time during the course of the study.
Moreover, in these four patients with nonpersistent wall
motion abnormalities, the magnitude of the inducible abnor-
malities generally followed a decreasing trend toward normal-
ization. In contrast, the other 11 patients (50%) developed
inducible abnormalities that remained persistent from test to
test (Group 3). This means that once they developed inducible
abnormalities, subsequent tests remained abnormal. In gen-
eral, both the magnitude and threshold level of inducible
ischemia worsened. For instance, it was not uncommon for
inducible abnormalities to progress toward rest regional dys-
synergy.
One patient among the group with no abnormalities on
serial testing (Group 1) was treated for acute rejection on two
occasions. Of the four patients with transient, inducible abnor-
malities (Group 2), two were treated on three occasions for
suspected allograft rejection. In one of these two patients,
despite ISHLT grade 0 rejection on endomyocardial biopsy,
the rest LVEF had decreased to 42% from 70% on the
radionuclide scan. There were four patients who were treated
for rejection in the group with persistent abnormalities (Group
3), including one with a negative biopsy.
Safety and side effects of DSE. Ninety-one DSE studies
were done in 22 patients. No major complication occurred at
any time during the DSE studies. No patient developed angina.
ECG changes suggestive of ischemia occurred once. Com-
monly reported side effects in this cohort included tremor
(7%), flushing (5%) and headache (2%). In addition, dizziness
occurred in 4% and shortness of breath in 2.4%. One patient
developed a three-beat run of nonsustained ventricular tachy-
cardia.
Endomyocardial biopsy. Acute cellular rejection requiring
augmented immunosuppressive therapy was diagnosed eight
Table 3. Comparative Demographic Data in Patients With and
Without Cardiac Events
Event Group No Event Group p Value
Donor age (yr) 22 6 11 26.5 6 11 NS
Recipient age (yr) 56.0 6 11 49.5 6 8.3 NS
Ischemic time (min) 146 6 18 160 6 44 NS
Time since transplantation (mo) 16 6 15 42 6 11 0.05
Cholesterol (mg/dl) 191 6 21 224 6 29 0.007
Baseline LVEF 55 6 3 55 6 4 NS
Data presented are mean value 6 SD. LVEF 5 left ventricular ejection
fraction.
Table 4. Number of Rejection Episodes and Angiograms and Date of Event in Three Subgroups of Patients
Pt
No.
No. of Rejection Episodes
Tx Date
Date of
First DSE
No. of DSE
Studies
No. of
Angiograms
Date of
Event
Cholesterol (mg/dl) Triglycerides (mg/dl)
During
Study Period
Before
Enrollment
Treated but
Negative Biopsy 1 Month 12 Months 1 Month 12 Months
Patients (n 5 11) With Persistent Abnormalities on Stress Echocardiogram
1 0 2 0 4/16/95 7/19/95 3 1 NE 215 195 253 195
2 0 0 0 5/8/92 11/4/92 3 3 3/8/96 178 241 378 80
3 1 0 0 1/1/94 6/2/94 3 1 3/24/95 210 181 83 58
4 0 0 0 6/9/94 8/8/94 3 1 10/10/95 329 184 328 106
5 0 0 0 8/21/93 1/19/94 7 2 12/5/95 304 225 191 149
6 0 0 1 2/27/93 3/1/93 4 3 2/14/96 229 224 246 303
7 0 0 0 7/21/95 9/21/95 5 1 3/11/96 171 192 317 135
8 0 0 0 7/22/94 4/29/94 3 1 11/20/94 271 85 243 85
9 1 0 0 2/19/93 7/15/93 6 1 5/12/94 220 256 99 256
10 1 0 0 5/4/94 5/20/94 4 2 NE 232 254 141 424
11 0 0 0 7/7/92 12/11/92 4 3 NE 181 159 177 276
Patients (n 5 4) With Transient Abnormalities on Stress Echocardiogram
12 0 0 0 2/13/94 4/15/94 6 2 NE 217 193 65 99
13 0 0 0 1/28/93 8/12/93 6 3 NE 179 255 114 362
14 0 0 0 8/14/92 12/21/92 3 3 NE 247 364 133 461
15 0 0 0 3/18/93 6/21/93 9 3 NE 262 293 205 247
Patients (n 5 7) With Normal Stress Echocardiogram
16 0 0 2 3/11/95 3/1/96 1 1 NE 257 217 68 224
17 0 0 0 11/22/94 1/3/95 3 2 NE 216 202 138 351
18 0 0 0 8/30/94 11/4/94 3 2 NE 216 248 431 571
19 0 0 0 9/9/92 12/4/92 4 3 NE 275 235 345 115
20 0 0 0 3/29/93 6/29/93 7 3 NE 222 193 68 125
21 0 0 0 12/21/93 4/1/94 2 3 NE 260 274 124 75
22 0 0 0 5/17/96 6/17/96 2 1 NE 205 203 115 194
NE 5 no event; Tx 5 transplantation; other abbreviations as in Table 2.
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times in five patients during the study. One additional patient
had been treated for cellular rejection two times before his first
enrollment into the study. Two other patients were treated
three times for suspected acute rejection, although their
subsequent biopsies demonstrated ISHLT grade 0 rejection.
There were significant reductions in the LVEF in these two
patients, which resolved after therapy. Table 4 gives the details
of biopsy relative to DSE and coronary angiographic studies.
Diagnostic cardiac catheterization. There were a total of
45 diagnostic cardiac catheterization procedures, with coro-
nary angiography performed in 22 patients. Each patient had
at least one cardiac catheterization done (mean 2, range 1 to
3). Coronary angiography revealed development of CAD in
seven patients (32%). One patient had bridging of the mid
LAD. Three others had significant narrowing of the LAD
(100% in 1, 60% in 2), whereas three had diffuse small-vessel
disease. The mean time from transplantation to detection of
angiographic disease or cardiac event was 16 6 15 months
(range 4 to 48). Table 2 gives a complete summary of the test
results. In addition, Table 4 gives the relative number of
angiograms and biopsies and their relation to wall motion
abnormalities in the three groups of patients.
Follow-up observations. The mean duration of follow-up
for the entire group was 32 6 11 months (range 5 to 50). The
end points were death, myocardial infarction (MI) and pres-
ence of angiographic CAD. During this period, 8 (36%) of 22
patients developed cardiac events. One patient had an acute
MI, as manifested by elevation of cardiac enzymes and ECG
changes. Diagnostic cardiac catheterization in this patient was
interpreted as normal. Seven (32%) of 22 patients eventually
developed angiographic CAD. Angiographic disease in the
seven patients included diffuse small-vessel disease in three
and LAD stenosis in the other four (bridging in 1, total in 1,
60% in 2). There were three cardiac deaths (14%). One of the
three patients with diffuse disease on the initial angiogram
died. Necropsy evaluation of the heart revealed massive MI
involving ;75% of the entire left ventricle. The coronary
anatomy of this patient confirmed severe three-vessel disease.
Representative light microscopic findings are depicted in Fig-
ure 1. The other two patients who died demonstrated LAD
disease. The diagnosis was made at autopsy in one patient. The
mean duration from transplantation to end point was 16 6 15
months (range 4 to 48) compared with a mean follow-up
period of 42 6 11 months (range 5 to 50) (p , 0.05) in those
without a cardiac event. There were no significant differences
between the patients without an event and those with an event
in terms of donor age (26.5 6 11 vs. 22 6 11 years), recipient
age (49.5 6 8.3 vs. 56 6 11 years) or ischemic time (160 6 43.5
vs. 146 6 17.9 min). Similarly, there was no difference in the
baseline LVEF (55 6 4% vs. 55 6 3%) (Table 3). No event or
coronary disease occurred in either the group with completely
normal stress echocardiograms or the group with transient
abnormalities (Groups 1 and 2). In contrast, 8 (73%) of the 11
patients with persistently abnormal DSE studies developed
angiographic CAD or MI, including three deaths (27%). In
other words, all clinical events and angiographic disease devel-
oped only in patients with persistent abnormalities on serial
DSE studies. The event rate for each of the three groups is
illustrated in Figure 2. In Group 3 patients who demonstrated
persistent wall motion abnormalities on serial testing, the
event rate was markedly increased and was related to allograft
CAD. The observed differences in the development of angio-
graphic CAD, death or MI (8 of 11 vs. 0 of 11 patients) was
significant (p 5 0.001). At an alpha level of 0.05, the power to
detect the observed differences was calculated at 94%.
Serum cholesterol at 1 month after transplantation was
lower in patients with events than in those without events
(191 6 21 vs. 227 6 29 mg/dl, p , 0.0070). The serum
cholesterol level at 1 year (246 6 51 vs. 234 6 52 mg/dl) and 2
years (228 6 32 vs. 227 6 44 mg/dl, p 5 NS) was similar for the
Figure 1. Histologic study of the coronary ar-
teries of one of the study patients. Note the
presence of myointimal hyperplasia involving
all of the coronary arteries, proximal (A) and
distal (B). Also note branch vessel occlusion
(arrow) and the absence of significant lipid
plaques. Hematoxylin-eosin 35, reduced by
35%.
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patients with an event and those without an event. Although
the initial cholesterol level was lower in the group with events,
the mean change in total cholesterol was significantly higher
(55 6 53 vs. 7.2 6 56.6 mg/dl, p , 0.04). Compared with the
group without an event, neither serum triglyceride levels at
baseline (1 month after transplantation), 1 year and 2 years nor
changes in the mean levels were significantly different between
the group with events and the group without events.
Patient outcome. The prognostic significance of the data is
displayed by the Kaplan-Meier curves shown in Figures 3 and
4. The analysis was done by comparing Group 3 with Groups 1
and 2. There were significant differences in all events or acute
MI and death combined. The cumulative risk of developing
angiographic CAD was significantly higher in those patients
who had persistently abnormal stress echocardiograms. The
survival rate was also significantly decreased for this group.
The rate of death and MI was 36% for this group. In contrast,
the event-free survival rate for patients with either normal
stress echocardiograms or transient abnormalities was 100%
(Fig. 3). We examined the effect of recipient and donor age,
serum cholesterol level, ischemic time, pretransplant diagnosis
and baseline LVEF on survival by using multivariate analysis.
None of these variables had any effect on the outcome. Only
the persistent, inducible wall motion abnormalities on serial
testing emerged as independent predictor of outcome.
Figure 2. Bar graph illustrating the
event rate in the three subgroups of
patients. The number of patients in
each group is represented by the
solid bar. The number of patients
who developed angiographic CAD
is represented by the open bar, and
the gray bar represents patients
with cardiac events. Note that an-
giographic CAD, death and MI oc-
curred only in the group with per-
sistent, inducible wall motion
abnormalities.
Figure 3. Kaplan-Meier survival distribution showing freedom from
all events (CAD, death and MI) as a function of time. Note that
event-free survival is markedly decreased for the patients with persis-
tent abnormalities on serial DSE (lower curve). In contrast, there was
absolute freedom from events in those patients with normal DSE
studies and transient abnormalities (upper curve), p , 0.002.
Figure 4. Kaplan-Meier plot illustrating freedom from death and MI.
Upper curve represents patients with normal DSE studies and those
with transient abnormalities. Lower curve is the survival distribution
for the group with persistent abnormalities on DSE and shows
decreased survival (p , 0.02).
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Discussion
Although the initial success rate is high (15), the long-term
outcome of heart transplant recipients is limited by accelerated
CAD (6). Accelerated CAD in heart transplant recipients is
difficult to diagnose, mainly because of the diffuse nature of the
disease. Our current understanding is evolving through the
studies of intracoronary ultrasound imaging, coronary endo-
thelial functional assessment, angiograms and a variety of
cardiac noninvasive tests. Taken together, the studies suggest
that the coronary disease process starts early, may involve
small vessels and then progresses rapidly.
Clinically, there are no specific signs and symptoms, and the
clinical presentation is often late and atypical (16). Histologi-
cally, the disease differs from typical atherosclerosis in that the
immune-mediated injury may be the primary initiating event
causing myointimal hyperplasia of smooth muscle cells and
subsequent lipid deposits that eventually compromise the
arterial lumen (17). The limitations of coronary angiography
(18) and standard noninvasive tests have been demonstrated in
many recent studies (2,6–8). It is important to ask questions as
to whether there are any potential risk factors that may modify
the disease process and outcome. A reasonable first step in
addressing some of these issues must include developing a
noninvasive test that is capable of identifying patients at risk
for developing angiographic CAD and subsequent cardiac
events. In this regard, the significance of the current study is
threefold: first, the development of wall motion abnormalities
that are persistent on serial testing identifies patients at risk for
poor outcome. Second, inducible wall motion abnormalities
early after transplantation are predictive of the eventual
development of angiographic CAD. Third, the DSE protocol is
feasible and safe soon after heart transplantation. Serial DSE
early after transplantation can be performed without signifi-
cant adverse consequences.
Although DSE has emerged as a reliable screening test for
allograft CAD (10,11), the experience to date has been limited
to patients with long-term transplants (.3 years), by which
time the disease is usually extensive and treatment options are
limited. We are unaware of any previous experience of serial
DSE in heart transplant recipients. This report extends our
previous observations on the usefulness of this simple, nonin-
vasive test in patients early after transplantation. The safety
profile documented previously (6,10–12) and in the current
study is reassuring. In the current study, no patient had any
major side effects. Nonsustained ventricular tachycardia of
three beats occurred only one time during 91 tests. Minor side
effects included headache, dizziness and dyspnea.
The relation between inducible ischemia and eventual
development of CAD is of great interest, although the mech-
anism(s) remain unknown. In the patient with a new trans-
plant, several factors, including rejection, postischemic myo-
cardial necrosis and infections, are known to cause left
ventricular dysfunction (1–3). Previous reports involving only
rest abnormalities suggest that rest wall motion abnormalities
or left ventricular dysfunction do not lead to poor outcomes
(3). We found only a small group of patients with normal rest
systolic function in whom the ischemic response to dobutamine
provocation developed at some time during serial testing. This
group of patients with transient abnormalities had no evidence
of angiographic disease on routine annual angiograms, and
their outcomes were similar to those with a completely normal
response. Unfortunately, the mechanism(s) of this transient,
inducible dysfunction cannot be answered by the current study.
The extent to which undetected cellular or vascular rejection
may have contributed to the transient abnormalities is un-
known. For reasons unclear, it appears that some transplant
recipients develop transient, inducible ischemia in response to
dobutamine stress. In contrast, a high percentage of patients
with inducible abnormalities that are reproducible on serial
tests eventually develop angiographic disease. The wall motion
abnormalities in this group are progressive, become more
extensive and develop at lower dobutamine dosages on serial
testing and may eventually progress to rest abnormalities.
The early disease is usually beyond the resolution of routine
angiography, and by the time stenosis of the epicardial vessels
is detectable, it is often advanced. In fact, this is consistent with
early reports of endothelial function (19), coronary flow re-
serve (20) and intravascular ultrasound imaging (21,22), which
all show that significant abnormalities are present in the setting
of “normal” coronary angiograms. The results of this study
show that the prognosis in patients with persistent, inducible
abnormalities is poor. These observations suggest that DSE
may have an important role in the routine follow-up evaluation
of heart transplant recipients. The current report, taken to-
gether with our previous findings (12) of the prognostic
significance of DSE in patients with heart transplants .5 years
old, indicates that abnormal DSE studies imply a poor out-
come in any transplant recipient with persistent, inducible
abnormalities. Furthermore, a negative DSE test suggests a
virtual absence of angiographic disease and implies a good
outcome regardless of the time since transplantation.
Clinical implications. The experience with DSE in new
heart transplant recipients is limited. For this reason we
believe it is premature to make any specific recommenda-
tions at this time. However, based on the consistency of the
results in patients with long-term transplants and results of
this study, we offer the following suggestions. Patients who
develop dobutamine stress–induced regional wall motion
abnormalities may need close monitoring and further stud-
ies, including coronary angiography and intravascular ultra-
sound imaging, to define the functional and anatomic
severity of CAD. The prognosis in these patients is poor
despite the absence of focal epicardial lesions on coronary
angiography, which, in fact, may represent advanced dis-
ease. Patients with persistent abnormalities on serial DSE
may need to be targeted for aggressive risk factor interven-
tions and close surveillance for possible early consideration
of retransplantation. In the light of increasing data showing
the reliability of DSE in screening for allograft CAD, it may
be argued whether routine coronary angiography should be
performed annually, as is presently done in most centers.
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The current study involves a relatively small number of
patients in one center, which provides important clues that
DSE may be of significant value in the screening and routine
management of heart transplant recipients. As the experi-
ence of this diagnostic test becomes more widespread, it
may allow us to reserve angiography for patients with
abnormal noninvasive tests and for those who present with
symptoms, especially if they are considered candidates for
interventional therapy.
Study limitations. In this study we evaluated the develop-
ment of CAD with angiography. It is well established that
intravascular ultrasound imaging is a far more sensitive
method to detect allograft CAD (21,22). It is conceivable that
the use of intravascular ultrasound imaging may have identi-
fied more patients with allograft CAD. Furthermore, we did
not take into account the potential influence of unidentified
vascular rejection on inducible wall motion abnormalities
observed transiently in Group 1 patients, owing to the fact that
we do not routinely perform histopathologic analysis for
vascular rejection. The extent to which vascular rejection
contributes to the development of allograft CAD, therefore,
cannot be determined from our study.
Conclusions. The results of this study demonstrate that it is
safe to perform DSE early after heart transplantation in stable
asymptomatic patients. We have also shown that abnormal
serial DSE studies are strongly predictive of the eventual
development of angiographic CAD and identify new transplant
recipients at risk for cardiac events. Large studies, preferably
multicenter in design, incorporating intracoronary ultrasound
methods may be invaluable in further defining the role of DSE
in the screening and management of accelerated CAD in the
heart transplant recipient.
References
1. Makita M, Tazelaar D, Billingham ME. Heart allograft rejection under
varying immunosuppressive protocols as evaluated by endomyocardial bi-
opsy. J Heart Transplant 1986;5:279–85.
2. O’Connell JB, Renlund DG. Diagnosis and treatment of cardiac allograft
rejection. Cardiovasc Clin 1990;20:147–62.
3. Radovancevic B, Birovljev S, Frazier OH. Treating cardiac allograft rejec-
tion: recent approach-analysis of 100 consecutive patients. J Heart Trans-
plant 1990;9:288–91.
4. Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with
acute cellular rejection and histocompatibility. J Heart Lung Transplant
1992;11:S90–103.
5. Hammond EH, Ensley RD, Yowell RL, et al. Vascular rejection of human
cardiac allografts and the role of humoral immunity in chronic allograft
rejection. Transplant Proc 1991;23:26–30.
6. Akosah KO, Olsolvsky M, Mohanty PK. Dobutamine stress-induced angina
in patients with denervated cardiac transplants: clinical and angiographic
correlates. Chest 1995;108:695–700.
7. Gao SZ, Schroeder JS, Hunt SA, Billingham ME, Valentine HA, Stinson
EB. Acute myocardial infarction in cardiac transplant recipients. Am J
Cardiol 1989;64:1093–7.
8. Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. 24th
Bethesda Conference: Cardiac Transplantation Task Force 5: complications.
J Am Coll Cardiol 1993;22:41–54.
9. Fyfe B, Loh E, Winters GL, Couper GS, Kartashov AI, Schoen FJ. Heart
transplantation-associated perioperative ischemic myocardial injury: mor-
pholigal features and clinical significance. Circulation 1996;93:1133–40.
10. Akosah KO, Mohanty PK, Funai JT, et al. Noninvasive detection of
transplant coronary disease by dobutamine stress echocardiography. J Heart
Lung Transplant 1994;13:1024–38.
11. Derumeaux G, Redonnet M, Schleifer DM, et al. Dobutamine stress
echocardiography in orthotopic heart transplant recipients. J Am Coll
Cardiol 1995;25:1665–72.
12. Akosah KO, Olsolvsky M, Kirchberg D, Salter D, Mohanty PK. Dobutamine
stress echocardiography predicts cardiac events in heart transplant patients.
Circulation 1996;94 Suppl II:II-283–8.
13. Gao S, Alderman EL, Schroeder JS, Hunt SA, Weiderhold MA, Stinson EB.
Progressive coronary luminal narrowing after cardiac transplantation. Cir-
culation 1990;82 Suppl IV:IV-269–75.
14. Kriett JM, Kaye MP. The Registry of the International Society for Heart
Transplantation: 7th official report 1990. J Heart Transplant 1990;9:323–30.
15. O’Connel JB, Bourge RC, Constanzo-Nordin M, et al. Cardiac transplanta-
tion: recipient selection, donor procurement and medical follow-up. Circu-
lation 1992;86:1061–79.
16. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac transplant
recipients: evidence of sensory reinnervation after cardiac transplantation.
N Engl J Med 1991;324:1791–4.
17. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987;
19:19–25.
18. Bajaj S, Shah A, Crandall C, et al. Coronary collateral circulation in the
transplanted heart. Circulation 1993;88(Pt. 2):263–9.
19. Fish RD, Nabel EG, Selwyn AP, et al. Responses of coronary arteries of
cardiac transplant patients to acetylcholine. J Clin Invest 1988;81:21–31.
20. Mason JW, Strefling A. Small vessel disease of the heart resulting in
myocardial necrosis despite angiographically normal coronary arteries. Am J
Cardiol 1979;44:171–6.
21. St Goar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound in
cardiac transplant recipients: in vivo evidence of “angiographically silent”
intimal thickening. Circulation 1992;85:979–87.
22. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR.
Presence of severe intimal thickening by intravascular ultrasonography
predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung
Transplant 1995;14:632–9.
1614 AKOSAH ET AL. JACC Vol. 31, No. 7
DOBUTAMINE STRESS ECHOCARDIOGRAPHY AFTER TRANSPLANTATION June 1998:1607–14
